Chinese Biopharmaceutical Start-Up EpimAb Closes $74M Series B Round

Login to View

EpimAb Biotherapeutics, a Shanghai-based biopharmaceutical company specializing in bispecific antibodies, announced on Wednesday the closing of a US$74 million series B round of financing jointly led by Chinese private equity fund manager SDIC Fund, and pharmaceutical and biotech-focused Sherpa Healthcare Partners.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in